Teva UK Patient/Carer Guide to the Safe Use of EFFENTORA®
Teva UK Patient/Carer Guide to the Safe Use of EFFENTORA®
Search by company, common medicine name, or title of Risk Minimisation Material
Teva UK Patient/Carer Guide to the Safe Use of EFFENTORA®
Teva UK Pharmacist's Guide for Dispensing EFFENTORA®
Teva UK Physicians Guide for Prescribing EFFENTORA®
Important information on the appropriate use of Elidel for HCPs
This website is for healthcare professionals (HCPs) and is based on the paper and electronic version of the Eliquis (apixaban) Prescriber Guide. The website contains information for HCPs to be aware of before prescribing apixaban and in particular is aimed at increasing awareness about the potential risk of bleeding with apixaban. The website includes information on increased bleeding risks with apixaban, guidance on the use of apixaban in patients undergoing surgery and invasive procedures, therapy management, management of overdose and haemorrhage. The site can be viewed using Firefox, Google Chrome or recent versions of Internet Explorer.
Patients prescribed Eliquis (apixaban) will receive a Patient Alert Card in the medication pack with the package leaflet. Please ensure you have read and understood the information in the card because it contains important safety information including the importance of taking apixaban regularly as instructed by the doctor, the main signs and symptoms of bleeding, and when to seek medical attention. Please carry the Patient Alert Card with you at all times and show it to every healthcare professional including pharmacists. Editorial updates were recently made to the card and the latest version of the card is dated January 2021. If you have lost the copy of the Patient Alert Card that is included in the medication pack, or it is damaged, please contact BMS Medical Information for a replacement copy (telephone: 0800 731 1736; e-mail: [email protected]).
This risk minimisation material is for Eliquis for all indications. Please ensure that you are familiar with this material before prescribing Eliquis as it contains important safety information on the potential risk of bleeding during treatment with Eliquis and provides guidance on how to manage that risk. Updates made to the Prescriber Guide in in May 2021 reflect changes to the Summary of Product Characteristics (SPC) for apixaban 2.5 mg and 5 mg tablets on ‘Patients with active cancer’. Other editorial changes were made including updates to the presentation of the Prescriber Guide. If you would like to obtain hard copies of the Eliquis Prescriber Guide and/or Patient Alert Card and/or SPCs, please contact Bristol-Myers Squibb Medical Information (telephone: 0800 731 1736; Email: [email protected]) with your specific request. Risk minimisation materials can only be delivered to UK registered healthcare premises.
Combined hormonal contraceptives: Q&As about the important information for women.
Important Information for women about risk of blood clots with combined hormonal contraceptives.
Elvanse - Chart for ongoing monitoring of lisdexamfetamine therapy - HCP
Elvanse - Checklist 1: lisdexamfetamine checklist before prescribing - HCP
Elvanse - Checklist 2: checklist for ongoing monitoring of lisdexamfetamine therapy - HCP
Elvanse - potential for non-medical use & diversion of prescription stimulant medications - Pt
Elvanse Adult - Chart for ongoing monitoring of lisdexamfetamine therapy - HCP
Elvanse Adult - Checklist 1: lisdexamfetamine dimesylate checklist before prescribing - HCP
Elvanse Adult - Checklist 2: checklist for ongoing monitoring of lisdexamfetamine dimesylate therapy - HCP
Elvanse Adult - potential for non-medical use & diversion of prescription stimulant medications - Pt
Enter your pen expiry dates below and we will remind you to re-order your prescription 30 days before via email. Alternatively you can download a calendar reminder to save in your phone or computer calendar.
Demonstration video to show you how to use your Emerade autoinjector pen.
Patient leaflet explaining about what you may need to do and who you should contact if taking various other medication.
Includes information for women that are taking other medicines and what you may need to do and who you may need to talk to.
The following list of questions is designed to support you in determining whether Emerres Una is a suitable choice of emergency contraceptive for an individual patient following unprotected sexual intercourse or contraceptive failure.
Renal and bone effects risk minimisation material: Tenofovir disoproxil for children and adolescents with HIV-1
Initiation of emtricitabine/tenofovir disoproxil for Pre-Exposure Prophylaxis (PrEP) Complete checklist at each visit and file in individuals medical record.
Information for individuals who have been prescribed emtricitabine/tenofovir disoproxil for Pre-Exposure Prophylaxis (PrEP)
Emtricitabine/ tenofovir disoproxil is indicated in combination with safer sex practices for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection in adults at high risk. This indication is based on clinical trials in men who have sex with men (MSM) at high risk for HIV-1 infection and on men and women in heterosexual serodiscordant couples.
You have been prescribed emtricitabine/ tenofovir disoproxil for PrEP (pre-exposure prophylaxis) to help reduce the risk of getting HIV-1 infection. For this medicine to work effectively it is important that you don’t miss doses. The recommended dose is one emtricitabine/ tenofovir disoproxil tablet each day. Take emtricitabine/ tenofovir disoproxil exactly as your doctor has told you.
Initiation of emtricitabine/tenofovir disoproxil for Pre-Exposure Prophylaxis (PrEP)
Information for individuals who have been prescribed emtricitabine/ tenofovir disoproxil for Pre-Exposure Prophylaxis (PrEP)
For Prescribers About emtricitabine/ tenofovir disoproxil for a Pre-Exposure Prophylaxis (PrEP) Indication
Information for individuals who have been prescribed emtricitabine/ tenofovir disoproxil for Pre-Exposure Prophylaxis (PrEP)
For Prescribers About emtricitabine/ tenofovir disoproxil for a Pre-Exposure Prophylaxis (PrEP) Indication
CHECKLIST FOR PRESCRIBERS Initiation of emtricitabine/tenofovir disoproxil for Pre-Exposure Prophylaxis (PrEP)
EMTRICITABINE/ TENOFOVIR DISOPROXIL FOR PrEP REMINDER CARD
IMPORTANT SAFETY INFORMATION For Prescribers About emtricitabine/ tenofovir disoproxil for a Pre-Exposure Prophylaxis (PrEP) Indication
IMPORTANT INFORMATION ABOUT EMTRICITABINE/TENOFOVIR DISOPROXIL TO REDUCE THE RISK OF GETTING HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION Information for individuals who have been prescribed emtricitabine/ tenofovir disoproxil for Pre-Exposure Prophylaxis (PrEP)
Important safety information for individuals using PrEP v2
Important safety information for prescribers v2 Tenofovir PrEP
Tenofovir HBV indications materials for children and adolescents
Tenofovir HIV indications materials for children and adolescents
Emtricitabine/Tenofovir disoproxil Checklist for Prescribers PrEP
Patient Brochure for Emtricitabine/Tenofovir disoproxil for PrEP (pre-exposure prophylaxis)
Important Safety Information for Prescribers About Emtricitabine/Tenofovir Disoproxil for a Pre-exposure Prophylaxis (PrEP) Indication
Patient Reminder Card for Emtricitabine/Tenofovir disoproxil for PrEP (pre-exposure prophylaxis).
Emtricitabine-Tenofovir Checklist for Prescribers-v2.0
Important educational information for Patients
Important safety information for prescribers-v2.0
This HCP guide is a condition of the Marketing Authorisation for Enhertu. It serves to minimise the important potential risk of medication error in addition to the SmPC. HCPs should read it before prescribing and administering Enhertu (trastuzumab deruxtecan). Risk of confusion between Enhertu (trastuzumab deruxtecan) and other trastuzumab-containing products including Kadcyla (trastuzumab emtansine).
This HCP guide is: - provided for HCPs to read before prescribing and administering Enhertu - an important tool to ensure the early recognition and diagnosis of ILD/pneumonitis, to allow prompt and appropriate treatment and minimise serious outcomes - a reminder to distribute a Patient Card to any patient receiving Enhertu treatment for the first time or if asked for a new copy
- This Patient Card has been provided to you because your doctor has prescribed you Enhertu. - This Patient Card helps you to identify symptoms of lung problems that you may experience with Enhertu. - Read this information before you start receiving Enhertu and before each infusion. - You should keep this card with you at all times and show it to any doctor you consult (for example if your regular doctor is unavailable or if you are travelling).
To be provided to patients receiving treatment with Entyvio by a HCP
Educational materials for the healthcare professional (doctor or pharmacist) Please read the full Summary of Product Characteristics before prescribing Envarsus
FOR DISPENSARY USE ONLY Warning Labels with Valproate Pregnancy Pictogram for Pharmacy to use with white box dispensing of these products. For hard copies of this information please contact medical information department on 0800 035 2525 or email [email protected]
THIS INTERACTIVE FORM IS NOT INTENDED FOR HARD COPY USE Interactive form for use with girls and women of childbearing potential taking this product. It is to be completed with their specialist at least once a year to make sure they know and have understood all the risks related to the use of valproate during pregnancy and the need to avoid becoming pregnant while taking valproate.
Educational material for Healthcare Professionals (HCPs) about the Pregnancy Prevention Programme. For hard copies of this information please contact medical information department on 0800 035 2525 or email [email protected]
Educational material for girls and women of childbearing potential about the Pregnancy Prevention Programme. For hard copies of this information please contact medical information department on 0800 035 2525 or email [email protected]
Educational material for girls and women of childbearing potential about the Pregnancy Prevention Programme. For hard copies of this information please contact medical information department on 0800 035 2525 or email [email protected]
FOR DISPENSARY USE ONLY Dispensary A4 Poster for Pharmacy with key information about the Pregnancy Prevention Programme. For hard copies of this information please contact medical information department on 0800 035 2525 or email [email protected]
Healthcare Professional (HCP) educational material, Pregnancy Prevention Programme
Patient Card for valproate in female patients - Contraception and Pregnancy Prevention
Patient Guide booklet for valproate in female patients - educational material, Pregnancy Prevention Programme
Checklist for prescribers related to valproate use in female patients
Pharmacy poster reminding that valproate must be prescribed and dispensed according to the Valproate Pregnancy Prevention Programme.
FOR DISPENSARY USE ONLY Warning labels with valproate pregnancy pictogram for pharmacies to use with white box dispensing of these products. For hard copies of this information please contact medical information department on +44 (0)1353 882875 or e-mail [email protected]
THIS INTERACTIVE FORM IS NOT INTENDED FOR HARD COPY USE Interactive form for use with girls and women of childbearing potential taking this product. It is to be completed with their specialist at least once a year to make sure they know and have understood all the risks related to the use of valproate during pregnancy and the need to avoid becoming pregnant while taking valproate.
Educational material for Healthcare Professionals (HCPs) about the Pregnancy Prevention Programme. For hard copies of this information please contact medical information department on +44 (0)1353 882875 or e-mail [email protected]
Educational material for girls and women of childbearing potential about the Pregnancy Prevention Programme. For hard copies of this information please contact medical information department on +44 (0)1353 882875 or e-mail [email protected]
Educational material for girls and women of childbearing potential about the Pregnancy Prevention Programme. For hard copies of this information please contact medical information department on +44 (0)1353 882875 or e-mail [email protected]
FOR DISPENSARY USE ONLY Dispensary A4 Poster for pharmacies with key information about the Pregnancy Prevention Programme. For hard copies of this information please contact medical information department on +44 (0)1353 882875 or e-mail [email protected]
Equasym - ADHD physicians guide to prescribing - July2021
Equasym - Chart for ongoing monitoring during methylphenidate treatment - HCP - July2021
Equasym - Checklist 1: checklist before prescribing - HCP - July2021
Equasym - Checklist 2: checklist for monitoring of ongoing therapy - HCP - July2021
The Patient card contains information on the following for patients treated with Erelzi: - Use in children and adolescents - Opportunistic infections and tuberculosis (TB) - Congestive Heart Failure (CHF).
This material is provided by Roche Products Ltd as a licence requirement for this medicine and forms part of the Risk Management Plan.
This material is provided by Roche Products Ltd as a licence requirement for this medicine and forms part of the Risk Management Plan.
This material is provided by Roche Products Ltd as a licence requirement for this medicine and forms part of the Risk Management Plan.
This material is provided by Roche Products Ltd as a licence requirement for this medicine and forms part of the Risk Management Plan.
This material is provided by Roche Products Ltd as a licence requirement for this medicine and forms part of the Risk Management Plan.
This material is provided by Roche Products Ltd as a licence requirement for this medicine and forms part of the Risk Management Plan.
This material is provided by Roche Products Ltd as a licence requirement for this medicine and forms part of the Risk Management Plan
Guide for pathologists dealing with gynaecological tissue which may have been exposed to Esmya (Ulipristal acetate) - revised Feb 2021.
This patient card will be present in the Esmya pack and is intended for the patient.
Health Professionals’ Guide containing important information about Espranor
This is an Educational Material, for health professionals to give to patients prescribed Espranor
This Patient alert card contains important safety information. The patient and, if appropriate their caregiver should be educated about treatment risks and provided with a Patient Alert Card.
This guide is developed to increase awareness and educate prescribers about the important identified risks of serious cardiovascular events of MI and stroke and of hypocalcaemia and important potential risk of ONJ, and the appropriate prevention, early diagnosis and adequate management of these events.
Please use this checklist in conjunction with the Summary of Product Characteristics during combined hormonal contraceptive (CHC) consultations.
Important Information for Women - Summary of risk of blood clots with combined hormonal contraception.
Leaflet with information on combined oral contraception to be given to the patient by the physician.
Instructions for use and a patient diary including medication record sheets for patients that have been prescribed Exelon Patch or Prometax Patch (rivastigmine transdermal system) to ensure the correct use of the patch.
Please keep this document safe for future reference. This booklet is only intended for patients that have been prescribed deferasirox. It contains important information, including how to take deferasirox the right way, why monitoring your treatment is important, and which medicines you can take while on deferasirox.
This booklet provides detailed information on posology and monitoring of patients on deferasirox, to minimise key adverse effects including medication errors during treatment.
Country-Specific Glucose Monitor List relating to patients on Extraneal (Icodextrin) PD solution
Your guide to Eylea - for the treatment of visual impairment due to macular oedema secondary to branch retinal vein occlusion (BRVO)
Your guide to Eylea - for the treatment of visual impairment due to myopic choroidal neovascularisation (myopic CNV)
Your guide to Eylea - for the treatment of visual impairment due to macular oedema secondary to central retinal vein occlusion (CRVO)
Your guide to Eylea - for the treatment of visual impairment due to diabetic macular oedema (DMO)
Information for parents and caregivers – for the treatment of retinopathy of prematurity (ROP)
Your guide to Eylea - for the treatment of neovascular (wet) age-related macular degeneration (AMD).
Are you a healthcare professional?
Are you a healthcare professional?